Apollon Formularies Plc - Interim Results for the 6 Months ended 30 June 2023
Apollon Formularies PLC / EPIC: APOL / Market: AQUIS / Sector: Biotechnology
APOLLON FORMULARIES PLC
(“Apollon” or the “Company”)
Interim Results
Apollon Formularies plc (AQUIS: APOL, "Apollon" or the "Company"), a based international medical cannabis pharmaceutical company trading on Aquis Stock Exchange, is pleased to report its interim results for the period ended .
I am pleased to provide shareholders with Apollon's unaudited interim results for the six months ended and update on the progress that the Company has made, and continues to make, as it takes steps to transition towards serving a wider global market. Building on the success of 2022, we achieved some important milestones in new international jurisdictions in the first half of 2023.
Intellectual Property Licensing
During the first quarter, Apollon has focused on licensing its intellectual Property (IP) portfolio along with its proprietary formulations and patient protocols to international strategic partners.
In , Apollon announced that it had granted an exclusive Licensing Agreement with Global Hemp Group (CSE: GHG) for (, and ). Under the terms of this exclusive license agreement, Global Hemp Group paid Apollon a fee of () and issued 10 million common shares in GHG to Apollon for a total consideration of . In addition, GHG will pay Apollon an ongoing royalty of 10% of gross revenue derived from sub-licenses and products stemming from this exclusive license agreement. Subsequently, GHG extended its exclusive license agreement to include the European Union with extension to and under the same royalty terms. GHG has completed and announced its first US sublicense under this agreement.
Post-Period
In , Apollon announced the granting of an exclusive license agreement to PureCann Pty Ltd., for the territory of . Under the terms of this agreement, PureCann paid Apollon an upfront exclusive license fee of £100,000. In addition, PureCann will pay Apollon an ongoing royalty of 6% on gross sales from products stemming from this exclusive license agreement. The license agreement with PureCann allows for continued expansion into , which represents a significant development for the Company as it provides access to and the Southern African Development Community (SADC), comprising of 16 member states with the potential to reach over 350 million people and eventually the entire African continent as more countries legalise medicinal cannabis with an extended addressable market of over 1.4 billion people.
PureCann intends to roll out a significant dispensary network providing cannabis based medicinal products with Apollon products forming the cornerstone of their business. Apollon stands to benefit greatly from PureCann’s current network where Purecann has contractual agreements with multiple GACP/GMP cultivators, where together we would have access to high-quality low-cost biomass reducing input costs dramatically across the production chain. PureCann also has access to two GMP extraction facilities meaning they can fully produce a complete range of certified cannabis based medicinal products’(CBMP's) for use locally within , but also for export markets within with medium term goals to export back into where together we would have a competitive advantage on cost across the board from plant to patient.
In , the Company signed a letter of intent with Supernature Co., Ltd for an Exclusive License Agreement for . Both Apollon and Supernature are currently working on the terms of the final Exclusive Licence Agreement which will be announced to the market in due course.
Asset Purchase
On , Apollon announced a new executed binding Letter of Intent (“LOI”) with Sproutly Canada, Inc. (CSE: SPR). Sproutly is a Canadian public company specialising in proprietary natural biologics drug discovery utilising a proprietary technique known as Aqueous Phytorecovery Process (APP), which extracts high-quality phytonutrients in their complete and proportional profiles. As applied to cannabis, APP can produce water-soluble cannabis solutions that can be stably formulated into medicinal products and traditional beverages without the use of artificial chemical and/or physical means to keep the cannabinoids dissolved in the water base.
The combination of Apollon's AI based therapeutic product formulation with demonstrated success in pre-clinical and clinical testing, clinical trial capability, manufacturing and production laboratories, with Sproutly's APP technology and natural water-soluble ingredients, creates a unique opportunity to develop, new natural biologic therapeutic products with increased bioavailability, faster therapeutic response times, lower patient dose requirements and increased product shelf life.
The binding LOI, allows Sproutly to acquire the assets of Apollon pursuant to an Asset Purchase Agreement. In exchange for the assets of Apollon, Sproutly will issue to Apollon a sufficient number of Sproutly shares so that Apollon will own 49% of the enlarged share capital of Sproutly, post-transaction. If the transaction takes place with the number of outstanding Sproutly shares as are currently in issue, and at an anticipated deemed price of (the price at which the trading of common shares of Sproutly was suspended), the effective valuation of the Apollon's assets will be (approximately £4.2million). If the number of Sproutly shares increases between now and the date of the transaction, the number of shares to be issued to Apollon will increase accordingly.
Sproutly and Apollon have granted each other a 60-day option to conduct due diligence, following which, if agreed to by both companies, the asset acquisition will be completed. The due diligence period may be shortened by mutual agreement. It is understood by the parties that Sproutly must complete one or more audits and take other legal and regulatory steps (the "Steps") to again become active and trading on the Canadian Securities Exchange ("CSE"). The Steps will proceed simultaneously with the due diligence period and the preparation and finalisation of necessary transaction agreements for a closing (the "Closing") of the transaction.
Outlook
The first half of 2023 was a busy and successful period for Apollon, and we are excited about the Company's prospects as we look towards 2024.
We are working extensively on ways in which to access the global market, by expanding our current capabilities to contract manufacturing in international GMP facilities in addition to the manufacturing, production operations and export opportunities we have currently in . The Company is working closely with our international partners to produce and distribute Apollon’s proprietary formulations. We will keep the market updated with any new developments.
We would like to thank our shareholders for their continued support and investment as we continue to work towards our goal of becoming the premier global medical cannabis and medicinal mushroom company in oncology and chronic pain.
Financials
For the six-month period ended the Group is reporting a loss of £
The interim report was approved by the Board of Directors and the above responsibility statement was signed on its behalf by:
Stephen D Barnhill M.D
Chairman
29 September2023
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
The Directors of the Group accept responsibility for the contents of this announcement.
For further information please visitor contact:www.apollon.org.uk
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
BlytheRay (Financial PR/IR-)
Tel: +44 207 138 3204
/Megan Ray
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
NOTES TO THE INTERIM FINANCIAL STATEMENTS
Apollon Formularies Plc is a medicinal cannabis pharmaceutical company incorporated and registered in the . The Company’s registered office is Quayside House, , Castletown, , IM9 1AS. The Company’s ordinary shares are traded on the Aquis Exchange Growth Market as operated by Aquis Stock Exchange Ltd (“AQUIS”).
2. Basis of Preparation
The condensed interim financial statements have been prepared in accordance with the Aquis Growth Market Rulebook.As permitted, the Company has chosen not to adopt IAS 34 “Interim Financial Statements” in preparing this interim financial information. The condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended . The interim financial statements have been prepared in accordance with adopted International Accounting Standards.
The interim financial information set out above does not constitute statutory accounts within the meaning of the Companies Act 2006. It has been prepared on a going concern basis in accordance with the recognition and measurement criteria ofadopted International Accounting Standards.
Statutory financial statements for the period ended were approved by the Board of Directors on . The report of the auditors on those financial statements was unqualified. The condensed interim financial statements are unaudited and have not been reviewed by the Company’s auditor.
Going concern
The preparation of financial statements requires an assessment on the validity of the going concern assumption. The Directors have reviewed projections for a period of at least 12 months from the date of approval of the financial statements as well as potential opportunities. Any potential shortfalls in funding have been identified and the steps to which Directors are able to mitigate such scenarios and/or defer or curtail discretionary expenditures should these be required have been considered.
The Directors are aware that the Group’s ability to remain a going concern for at least 12 months from the approval of these financial statements is dependent on the Group’s ability to raise further equity and/or debt finance. This is expected to happen within the going concern period of the next 12 months.
In approving the financial statements, the Board has recognised that these circumstances create a level of uncertainty. However, having made enquiries and considered the uncertainties outlined above, the Directors have a reasonable expectation that the Group will continue to be able to raise finance as required over this period to enable it to continue in operation and existence for the foreseeable future. Accordingly, the Board believes it is appropriate to adopt the going concern basis in the preparation of the financial statements.
Risks and uncertainties
The Board continuously assesses and monitors the key risks of the business. The key risks that could affect the Group’s medium term performance and the factors that mitigate those risks have not substantially changed from those set out in the Group’s 2022 Annual Report and Financial Statements, a copy of which is available on the Group’s website:.The key financial risks are market risk, exchange rate risk, liquidity risk and credit risk.www.apollon.org.uk
Critical accounting estimates
The preparation of condensed interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the end of the reporting period. Significant items subject to such estimates are set out in Note 2 of the Group’s 2022 Annual Report and Financial Statements. The nature and amounts of such estimates have not changed significantly during the interim period.
3. Accounting Policies
The same accounting policies, presentation and methods of computation are followed in the interim consolidated financial information as were applied in the Group’s latest annual audited financial statements except for Intangible assets and those that relate to new standards and interpretations effective for the first time for periods beginning on (or after) and will be adopted in the 2023 annual financial statements.
A number of new standards, amendments and became effective on and have been adopted by the Group. None of these standards have materially affected the Group.
3.1 Basis of preparation of financial statements
The Group Financial Statements consolidate the Financial Statements of the Company and its subsidiaries made up to . Subsidiaries are entities over which the Group has control. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.
Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:
The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the period are included in the Group Financial Statements from the date the Group gains control until the date the Group ceases to control the subsidiary.
Investments in Group undertakings are stated at cost, which is the fair value of the consideration paid, less any impairment provision. The financial statements of the subsidiary are prepared for the same reporting period as the Group. When necessary, adjustments are made to bring the accounting policies in line with those of the Group.
Where necessary, adjustments are made to the Financial Statements of subsidiaries to bring the accounting policies used in line with those used by other members of the Group. All significant intercompany transactions and balances between Group enterprises are eliminated on consolidation.
3.2 Intangible assets
Intangible asset expenditure relates to patents and associated data acquired.
Intangible assets are only capitalised if the costs can be measured reliably and will generate future economic benefits in the form of cashflows to the Group.
Intangible assets are not subject to amortisation but are assessed annually for impairment. The assessment is carried out by allocating the patent assets to cash generating units (“CGU’s”), which are based on specific projects. The CGU’s are then assessed for impairment using a variety of methods including those specified in IAS 36.
Whenever the patent assets in cash generating units does not lead to the desired research outcome and the Group has decided to discontinue such activities of that unit, the associated expenditures are written off to the Statement of Comprehensive Income.
The Group is not income generating as yet and therefore there has been no amortization since acquisition. Patents and associated data will be amortized when the Group starts generating revenue relating to the assets.
Asset are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell.
IP assets (comprising patents) acquired by the Group as a result of a business combination are initially recognised at fair value or as a purchase at cost and are capitalised.
Internally generated IP costs are written off as incurred except where IAS 38 criteria, as described in research and development above, would require such costs to be capitalised.
The Group’s view is that capitalised IP assets have a finite useful life and to that extent they should be amortised over their respective unexpired periods with provision made for impairment when required. Capitalised IP assets are not amortised until the Group is generating an economic return from the underlying asset and as such no amortisation has been incurred to date as the products to which they relate are not ready to be sold on the open market. When the trials are completed and the products attain the necessary accreditation and clearance from the regulators, the Group will assess the estimated useful economic like and the IP will be amortised using the straight-line method over their estimated useful economic lives.
4. Dividends
No dividend has been declared or paid by the Group during the six months ended (six months ended : £nil).
5. Earnings per Share
The calculation of loss per share is based on a retained loss of £763,796for thesixmonths ended (
No diluted earnings per share is presented for thesixmonths ended or
6. Associate
On , the Legal Subsidiary acquired a right to receive a 49% equity interest in Apollon Formularies Jamaica Limited (“Apollon Jamaica”), a company incorporated in , upon approval by the Cannabis Licensing Authority (CLA) of for Company to so own such equity in a medically licensed cannabis company. In the interim, the Company entered into a contract with Apollon Jamaica whereby the Company receives 95% of the net profits of Apollon Jamaica. The Legal Subsidiary also entered into a contract with its shareholder, , M.D., who is the person presently recognised as the owner of such 49% equity interest in Apollon Jamaica, that he: (i) pledges to assign such equity to Company upon CLA approval of Company being an owner, (ii) commits to vote the equity he holds in Apollon Jamaica in accordance with such assignment obligation to the extent permitted by law, and (iii) will participate as a director of Apollon Jamaica and act when voting in a way that is consistent with such equity commitments to the Company to the extent permitted by law.
Apollon Jamaica is accounted for as an associate because the Legal Subsidiary has significant influence over it, has a representative serving as a director who participates in its policy-making process, and has engaged in material transactions with it that includes loans and a right to receive 95% of its profits.
These factors have been determined to be sufficient to meet the requirements of IAS 28 even though the Company does not presently own any equity in Apollon Jamaica and, once it does, will only receive a 49% share of the return on investment (which will come from the 5% net income) and only have 49% voting rights.
As an associate, Apollon Jamaica is accounted for on an equity accounting basis.
The carrying value of the investment in the associate is determined as follows:
The Company’s share of Apollon Jamaica result for the year was a loss of £5,035 (2022: loss of £45,386) of a total loss of £10,275 (2022: total loss of £92,624). The share of the loss in associate for the period ended is restricted to the carried forward investment in associate and has therefore been recognised as £nil. As a result, the remaining investment balance carried forward from the period ended remains at £nil.
7. Asset Held for Sale
Following the mutual termination of the proposed asset disposal to Global Hemp Group, on, the Company entered into a binding letter of intent (“LOI”) with
Under the terms of the LOI,Sproutlywill acquire all the Assets of Apollon Formularies plc, other than cash, cash equivalents, and accounts receivables, for a payment of 350,000,000 Sproutly common shares at a deemed price of per share, for a total consideration of . If the number of
Sproutly and Apollon have granted each other a 60-day option to conduct due diligence, following which, if agreed to by both companies, the asset acquisition will be completed. The due diligence period may be shortened by mutual agreement.
The value of Asset Held for Sale is the expected sale proceeds from Sproutly, being the total consideration of shares and cash, converted into pounds sterling using the exchange rates on being .
8. Available for sale investment
The movement in available for sale investments during the period was as follows:
9. Trade and Other Payables
The carrying amounts of the Group’s trade and other payables are denominated in pounds sterling.
10. Director Loan
During the year ended , the Company entered into a loan agreement with Director . The term of the loan is 12 months (extendable for an additional 12 months by mutual agreement) and bears an interest rate of 8% pa. is also a shareholder of the Company. At as , the Company owes £152,305.
11. Events after the reporting date
On , the Group entered into a binding letter of intent (“LOI”) with
12.Approval of interim financial statements
The Condensed interim financial statements were approved by the Board of Directors on .
**ENDS**
Notes 6 months to 30 June 2023 6 months to 30 June 2022
Unaudited£ Unaudited£
Continuing operations
Revenue 47,551 165,053
Administration expenses (450,625) (535,889)
Foreign exchange (91,533) 203,786
Operating loss (494,607) (167,050)
Share on loss from - (45,386)
associate
Other gains/(losses) 8 (273,171) -
Finance costs 3,982 -
Loss before tax for the (763,796) (212,436)
period
Tax - -
Loss for the period (763,796) (212,436)
Total comprehensive (763,796) (212,436)
income for the period
Total comprehensive
income for the period (763,796) (212,436)
attributable to equity
holders
Earnings per share from
continuing operations
attributable to the
equity owners of the
parent
Basic and diluted ( (0.1)p (0.03)p
per share)pence 5 Notes As at30 June 2023 As at31 December As at30 June 2022
Unaudited£ 2022 Audited£ Unaudited£
Non-Current Assets
Intangible Assets 7 - - 384,056
Available for Sale 8 15,485 - -
Investments
Investments in 6 2,829,140 2,996,788 2,625,721
associate
2,844,625 2,996,788 3,009,777
Current Assets
Trade and other 677,267 593,262 645,283
receivables
Cash and cash 50,934 389 2,653
equivalents
728,201 593,651 647,936
Asset held for Sale 7 384,056 384,056 -
Total Assets 3,956,882 3,974,495 3,657,713
Current Liabilities
Trade and other 9 1,842,475 1,096,292 619,442
payables
1,842,475 1,096,292 619,442
Total Liabilities 1,842,475 1,096,292 619,442
Net Assets 2,114,407 2,878,203 3,038,271
Equity
Share premium 54,671,250 54,671,250 54,338,863
Share option reserve 85,363 85,363 85,363
Reverse acquisition (47,030,385) (47,030,385) (47,030,385)
reserve
Retained losses (5,611,821) (4,848,025) (4,355,570)
Total Equity 2,114,407 2,878,203 3,038,271Share Share option Reverse Retained Total
Note premium£ reserve£ Acquisition losses£ equity£
Reserve£
Balance as at
1 January 54,050,764 85,363 (47,030,385) (4,143,134) 2,962,608
2022
Loss for the - - - (212,436) (212,436)
period
Other
comprehensive
income for
the year
Items that
may be
subsequently
reclassified
to profit or
loss
Total
comprehensive - - - (212,436) (212,436)
income for
the year
Share issue 288,099 - - - 288,099
Total
transactions
with owners, 288,099 - - - 288,099
recognised in
equity
Balance as at 54,338,863 85,363 (47,030,385) (4,355,570) 3,038,271
30 June 2022
Balance as at
1 January 54,671,250 85,363 (47,030,385) (4,848,025) 2,878,203
2023
Loss for the - - - (763,796) (763,796)
period
Other
comprehensive
income for
the year
Items that
may be
subsequently
reclassified
to profit or
loss
Total
comprehensive - - - (763,796) (763,796)
income for
the year
Total
transactions
with owners, - - - - -
recognised in
equity
Balance as at 54,671,250 85,363 (47,030,385) (5,611,821) 2,114,407
30 June 2023Notes 6 months to 30 June 6 months to 30 June 2022
2023Unaudited£ Unaudited£
Cash flows from operating
activities
Operating loss (763,796) (212,436)
Adjustments for:
Loss from associate - 45,386
Finance costs 10 5,856 -
Decrease in trade and other (87,005) (284,626)
receivables
Increase/(decrease) in trade 722,658 440,469
and other payables
Foreign exchange 91,533 (203,786)
Net cash used in operations (30,754) (214,993)
Cash flows from investing
activities
Proceeds from sale of 8 13,147 -
investments
Loans granted (to)/from 76,115 (87,340)
associate
Net cash used in investing 89,262 (87,340)
activities
Cash flows from financing
activities
Loan repaid to director 10 (7,963) -
Net cash generated from (7,963) -
financing activities
Net (decrease)/increase in 50,545 (302,333)
cash and cash equivalents
Cash and cash equivalents at 389 304,986
beginning of period
Cash and cash equivalents at 50,934 2,653
end of period1. General Information
-- The contractual arrangement with the other vote holders of the investee;
-- Rights arising from other contractual arrangements; and
-- The Group’s voting rights and potential voting rights1. 1. Asset held for sale
1. 1. Intellectual property (IP)
30 June 2023£ Investment in associate At beginning of period - Share of loss in associate - At end of period -
Loans to Associate At beginning of period 2,996,788 Loans granted from associate (76,115) Foreign exchange (91,533) At end of period 2,829,140 Total 2,829,140
Available for sale investments £ Balance as at - 10,000,000 shares in Global Hemp Group Plc 301,803 Sale of Global Hemp Group Plc Shares (13,147) Fair value adjustment (273,171) As at 15,4851 January 2023 30 June 2023
Current: 30 June 2023£ 30 June 2022£
Trade payables 1,113,012 503,509
Directors Loan (note 10) 152,305 -
Tax and payroll 19,976 19,976
Other creditors 557,182 95,957
1,842,475 619,44230 June 2023£ Opening balance 154,412 Loans granted 6,000 Loans repaid (13,963) Interest 5,856 Closing balance 152,305

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE